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Purpose:  To determine the dosimetric accuracy of a dose reconstruction method used for 
verification of helical tomotherapy delivery for three different clinical sites. 
Methods and Materials:  A delivery verification and dose reconstruction method has been 
applied to helical tomotherapy treatment plans of three different treatment sites (head & neck, 
prostate and lung).  Treatment plans were generated on a cylindrical measurement phantom 
(TomoPhantom) using contours, prescriptions and planning objectives taken from clinical patient 
plans of the three sites.  Film and ion chamber measurements were made for each plan with and 
without intentional changes in the machine output [-4% to 4%] or leaf open times [-30 ms to +30 
ms] to the planned delivery. 
A TomoTherapy delivery verification tool uses pulse-by-pulse machine CT detector and 
transmission ion chamber data, extracted at the conclusion of each delivery, to determine the 
incident energy fluence delivered for each projection.  Dose reconstruction was calculated by 
simulating the delivered energy fluence onto the planning CT.  The reconstructed doses were 
compared with both the measured and planned dose distributions. 
Results:  Measured dose variations for repeated daily deliveries were small, typically within 2%.  
Greatest differences between the measured dose and planned dose occurred when intentional 
changes in leaf open times (±30 ms) were made to the delivery.  Measured doses from all 
deliveries were well predicted by the dose reconstruction method, which demonstrated 
agreement for point doses to within 2%.  The dose reconstruction method also demonstrated 
acceptable agreement with the film dose measurements for all three plans.  Comparison of film 
versus reconstructed dose for all cases showed that over 90% of a selected region of interest had 
a gamma index of less than 1. 
xi 
 
Conclusion:  The method of dose reconstruction based on machine detector data can account for 
daily variations in the delivered dose due to machine error.  Dosimetric accuracy for the method 






















CHAPTER 1.  INTRODUCTION 
1.1 Background and Significance 
1.1.1 Goals and Advances in Radiation Therapy 
The goal of radiation therapy is to deliver as much dose as necessary to destroy cancerous cells 
while minimizing or limiting the dose to normal healthy tissues.  It begins at the treatment 
planning stage where planning target volume (PTV) and organs at risk (OARs) are defined
1, 2
 on 
a treatment planning CT image dataset of a patient taken while in treatment position.  The PTV 
covers the gross tumor volume (GTV) with additional margin to account for microscopic cancer, 
effects of organ and patient movements, radiation beam inaccuracy and set-up uncertainty 
(Figure 1).  OARs are normal healthy tissues near the PTV that have set tolerances for radiation 
dose and are the limiting factors during treatment planning.   Dose objectives for PTVs and 
OARs are influenced by the overall treatment objective (curative or palliative).  Once PTV and 
OARs have been determined, the next step is to determine which modality of treatment is best 
suited to achieve the goal of a favorable outcome for the patient.  This includes the method of 
treatment (brachytherapy, external beam, intra-operative, etc.), the type of radiation (photons, 
electrons, protons, etc.) and energy selection. 
 
Figure 1. Illustration of PTV (blue) coverage that includes the GTV (red), microscopic 
extension (green) and setup error 
2 
 
One of the latest advances in radiation delivery is intensity modulated radiation therapy 
(IMRT).  IMRT is a treatment delivery method that uses optimized non-uniform or modulated 
beam intensities to deliver a highly conformal dose distribution within a patient.
3, 4
  The benefit 
of this method is the ability to escalate dose to cancerous cells while decreasing the maximum 
dose to the surrounding normal tissues.  The result is higher tumor control probabilities and/or 
lower normal tissue complication probabilities.  However, these advantages assume that the 
patient’s anatomy is in the same position at the time of treatment as they were during the 
treatment planning CT.  If the tumor were to shift or change size or shape from the planned 
image during treatment delivery, it may not receive the planned radiation dose coverage.  
Furthermore, a normal tissue adjacent to the tumor could receive too much dose. 
The different ways to deliver an IMRT treatment may be divided into gantry static (i.e., 
multiple field originating from different fixed positions) and gantry dynamic delivery techniques.  
Gantry static techniques typically achieve beam modulation through the use of multi-leaf 
collimator (MLC), although compensator filters or beam scanning are sometimes used.  MLC 
leaf positions are adjusted during the treatment to define field shapes or segments.  Gantry static 
MLC techniques may be further divided into segmental (SMLC), where no radiation is delivered 
during leaf movement or dynamic (DMLC), where radiation is delivered during leaf movement.  
Gantry dynamic techniques include intensity modulated arc therapy (IMAT) and serial and 
helical tomotherapy.  Tomotherapy delivery systems use a binary MLC where the leaf positions 
are either open or closed at any point in time during the treatment. 
The importance that IMRT places on the reproducibility of patient’s position has 
motivated developments in image-guided radiation therapy (IGRT).  The basis of IGRT is to take 
an image of the patient immediately prior to or during the treatment to verify and adjust (if 
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Figure 2. TomoTherapy 
Hi·ART 
delivery system 
necessary) the patient’s position so that he/she is in the same position as the time the planning 





, kilovoltage CT (kVCT)
7, 8




1.2.1 Introduction to the Hi·Art Delivery System 
The TomoTherapy Hi·Art delivery system is 
one of the latest advancement in radiotherapy that is 
capable of both a helical IMRT delivery and a MVCT 
IGRT imaging system within the same unit (Figure 
2).
10
  The radiation source used for both treatment and 
imaging is a linear accelerator (linac) with nominal 
photon beam energies of 6 MV and 3.5 MV, 
respectively.  The linac rotates on a slip-ring gantry 
about a fixed axis located 85 cm from the source.  The field width in the longitudinal direction is 
defined by a pair of collimating jaws that have an adjustable range of 0.6-5.0 cm at the axis of 
rotation.  The field length in the lateral direction is defined by a 64-leaf binary MLC.  Each leaf 
of the MLC has a projected width of 6.25 mm at 85 cm from the source which allow for a field 
length ranging from 0-40 cm, depending on the number of open leaves. 
The imaging detectors for TomoTherapy consist of 738 gas-filled xenon ion chambers 
aligned in an arc located on the opposite side of the gantry from the radiation source (Figure 2).  
Due to the maximum field length, the MVCT image is limited to a 40 cm field of view (FOV) 
instead of the standard 50 cm FOV in a conventional CT.  Of the 738 detector channels, only the 
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central 640 records exit beam data.  The radiation emitted through each open leaf will expose 
approximately 7 exit detectors.  Detector data are recorded at a rate of 300 pulses per second. 
Helical treatment is delivered by moving the couch through the rotating gantry at a 
constant speed.  The distance the couch moves per gantry rotation is equal to the selected field 
width times a user-selected pitch.  In the treatment planning process, each rotation is divided into 
51 projections, or beams incident from fixed, equally-spaced (approximately every 7°) gantry 
angles.  In a typical treatment plan, there may be up to several thousand projections, depending 
on the length of the PTV(s) and the selected pitch.  IMRT delivery is achieved by optimizing the 
time each of the 64 leaves remains open per projection in the treatment planning process. 
1.2.2 Delivery Subsystem 
During treatment, the delivery subsystem software components assist in reading, 
translating, and transferring data.  One component in particular, the Data Acquisition System 
(DAS), translate photon counts from the transmission monitor chambers (located between the 
beam source and collimating jaws) and exit detectors into raw detector data.  TomoTherapy 
stores this data defining the machine state over time in the form of sinograms.  A number of 




• Leaf control sinogram:  The planned leaf open time versus projection number per 
delivery.  It has a matrix of 64 by the number of projections (Nproj) for the treatment plan.  
The values within this sinogram are fractions of leaf open time per projection. 
• Treatment detector sinogram:  The number of counts per pulse (300 pulses/sec) for the 
centrally located 640 detectors (out of the 738) and the 3 monitor chambers.  This 
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sinogram is a matrix of 643 (first 640 are exit CT detector data, last 3 are output data) × 
(300 pulses/sec × delivery time [sec]). 
• Delivery Verification (DV) sinogram:  The computed effective leaf open time versus 
projection number of a delivered treatment based on the treatment detector sinogram.  
The matrix size and value range for each cell are the same as the leaf control sinogram. 
It is important to note that there is a leaf control sinogram file for each scheduled fraction within 
a plan.  Therefore, a plan that has 38 fractions will have 38 leaf control sinogram files. 
1.2.3 Image-guided Radiation Therapy (IGRT) 
IGRT on TomoTherapy is achieved by initially taking an MVCT scan of the patient in 
treatment position prior to a treatment delivery.  The MVCT image is overlaid with the planned 
image to allow for manual or auto registration.  If a shift is needed to align patient into the 
planned position, the TomoTherapy Hi·Art system can automatically shift the couch laterally, 
longitudinally and vertically.  Tilt misalignment in the sagittal plane cannot be corrected by the 
system.  However, tilt misalignment in the axial plane can be corrected for by offsetting the 
delivery angle accordingly. 
As mentioned in section 1.2.2, during treatment delivery, the DAS records exit detector 
data from the same detectors used for imaging.  This data can be used to detect errors in 





1.3 Delivery Verification and Dose Reconstruction 
1.3.1 Deviations Associated with Treatment Delivery 
Although IGRT can be beneficial in properly positioning the patient, it does not correct 
for changes in the patient anatomy throughout treatment.  Changes to patient anatomy can affect 
the delivered dose in two ways.  First, the radiation transmission through the patient will be 
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altered if the patient changes shape over the course of treatment.  This effect may be due to the 
patient gaining or losing weight or through tumor shrinkage during the course of treatment.  
Second, the radiation dose to the PTV and/or OAR structures may change if they are deformed 
relative to their shape at the time of treatment planning. 
In addition to changes in patient anatomy, deviations from the planned incident radiation 
fluence will also affect the administered dose.  Minor deviations (i.e., within machine tolerance) 
in machine output will change the delivered dose to the patient.  Although IGRT may be used to 
determine patient anatomical changes, it does not account for deviations from the planned 
delivery associated with the machine. 
If daily changes to the delivered dose can be accounted for, the patient’s plan can be 
modified during the course of treatment.  The process is commonly known as “adaptive 
radiotherapy” within the field of practice.
14
 
1.3.2 Methods to Account for Deviated Treatment Delivery 
Within the TomoTherapy Hi-Art system, a number of methods to correct for changes in 
delivered dose have been proposed and/or implemented.  In TomoTherapy Planned Adaptive 
(PA
TM
) program, the effect of changes to patient anatomy is accounted for by re-computing the 
radiation dose on the daily MVCT taken prior to treatment.  This process has been described by 
Langen et al.
15
   Because the MVCT image dataset is smaller (e.g., 40 cm field of view) than the 
planning kVCT image dataset (e.g., typically 50 cm), a composite or merged image dataset of the 
MVCT and the kVCT is created for the dose recomputation.  For the merged image, the kVCT 
covers all the image area where the MVCT did not cover relative to the planning image. 
Since an MVCT image will be used for dose computation, it is imperative that the image 
value-to-density table (IVDT) applied to the MVCT image corresponds to a similar density as 
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the planning kVCT image for the same structure.  The determination and constancy of IVDTs for 
the Hi-Art system has been discussed by Langen et al.
15
 
Although the dose may be recomputed on the daily MVCT image, the clinical impact of 
these variations is difficult to quantify unless contour changes in the PTV(s) and OAR(s) have 
been accounted.  The process of registering a daily treatment image to the planning CT that 
account for internal anatomical changes is known as deformable registration.
16
  Once the new 
PTV and OAR have been registered, the cumulative dose to the structures can be recomputed by 
applying the planned delivery parameters (machine parameters such as output dose rate, leaf 
open sequence, gantry & couch speed and beam field size) onto the registered image.  This dose 
can then be compared to the planned dose to determine whether a new plan is necessary to 
compensate for dose differences in the PTV and OAR.  Lu et al.
16
 discussed the use of 
deformable registration for TomoTherapy Hi-Art planning systems. 
To account for delivery deviations during treatment, it is necessary to include changes in 
machine parameters which affect the delivered dose.  This process is sometimes referred to as 
delivery verification (DV).
11
  Kapatoes et al described a technique where the incident energy 
fluence (Ψ) can be determined by multiplying the treatment exit-detector signal (s) by the 
inverse of a measured transfer matrix (D). 
                                                           
1−= ⋅Ψ D s                                                             (1) 
With the incident energy fluence from Eq. (1) and an IGRT image, dose may be calculated with 
actual, rather than planned, delivery parameters.  The incorporation of actual (verified) delivery 
parameters into the dose calculation on the daily IGRT image is known as dose reconstruction 
(DR)
17
.  Implementing DV and DR into adaptive planning should improve the evaluation of 


































































































1.4 Delivery Verification for TomoTherapy 
1.4.1 General Concerns 
Unlike conventional linear accelerator, TomoTherapy does not deliver a plan according 
to the planned monitor units (MUs) which is related to radiation dose.  Instead, the delivery is 
governed by treatment time that assumes a constant beam output, similar to that of traditional 
Co-60 therapy unit (uses an isotope as source of radiation).  For the Hi·Art system, the delivered 
dose can deviate from the planned dose since TomoTherapy’s beam output are allowed to vary 
throughout a treatment delivery by up to 5% over a 5 second interval without interlocking the 
machine.
18
  An illustration of this output variation as seen from a sample patient treatment 
delivery is shown in Figure 3, which displays the normalized signals obtained from the three 
transmission monitor chambers versus projection number.  Notice that the variation is cyclical 
with rotation (51 projections per rotation) and also show a long term drift. 
 
Figure 3. Normalized output reading from the three transmission monitor 
chamber during a typical patient treatment delivery on TomoTherapy 
 
Output deviation may also be due to differences between the planned and actual leaf open 
times that are a result of mechanical issues of the 64 leaves and/or their controlling components.  
9 
 
In the Hi-Art system, the machine delivery tolerance is set to stop treatment if there are four 
instances where an individual leaf’s open time is different by more than 32 ms from the planned 
leaf opening time.  Differences less than this value may affect the delivered dose without 
interlocking the machine. 
TomoTherapy stores transmission monitor chambers and exit detector data for each 
individual treatment delivery in the form of a treatment detector sinogram (defined previously).  
The number of counts per pulse recorded by each exit detector is dependent on whether the 
leaves are opened or closed, the beam’s radiological path length through all structures (e.g., 
patient, couch, etc.) between the source and the exit detector, and the beam output.  
Determination of the energy fluence as a function of off-axis position is possible but requires 
knowledge of the patient position and the transmission characteristics of the beam through the 
patient.
17
  However, if we assume that the beam’s profile remains constant during delivery, then 
changes in the energy fluence rate through each leaf would be proportional to the signal of the 
transmission monitor chambers.  For each projection, the total energy fluence that is emitted 
through each leaf would then be proportional to the amount of time each leaf remains open. 
1.4.2 TomoTherapy DVPA software program 
TomoTherapy has developed a delivery verification planned adaptive (DVPA
TM
) 
program that can reconstruct the dose based on the DV sinogram and MVCT image data.  The 
algorithm used for dose calculation in DVPA is the same as that used within the TomoTherapy 
treatment planning system (TPS) and assumes a constant beam output for dose calculation.  To 
account for beam output variations during delivery in the reconstructed dose calculation, DVPA 
adjusts each measured leaf open time per projection by the percentage of the difference between 
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measured beam output and planned beam output over the period of that projection.  The adjusted 
leaf open time is defined as the effective leaf open time. 
The energy fluence emitted though an open MLC leaf irradiates approximately 7 exit 
detectors.  Leaf open time per projection for each leaf is determined in DVPA by taking the 
average full width-half max (FWHM) of the 5 central detectors’ (of the 7) signal profile (Figure 
4).  Thus, the delivered energy fluence can be determine by scaling the beam’s intensity up or 
down based on the measured output data and use the rise and fall times of the exit detector 




Figure 4. Signal reading from one exit detector over 300 pulses 
 
Once DVPA determines the effective leaf open time for all projections of a delivery, it 
creates the DV sinogram.  The energy fluence throughout the delivery is derived from the DV 
sinogram and the planned beam output.  A reconstructed dose is then computed by applying the 
energy fluence onto the MVCT image taken for the delivered plan.  Figure 5 illustrates the path 

















FWHM = leaf open time
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For this study, we will apply DV and DR method for helical tomotherapy delivery to 3 
simulated patient plans (head & neck, prostate and lung) applied to a single phantom image 
dataset.  Each plan will be delivered with and without intentionally-introduced offsets (within 
machine delivery interlocks limit).  Comparison between the reconstructed and measured dose 




Figure 5. Block diagram of DV and DR for TomoTherapy 
1.5 Hypothesis and Specific Aims 
1.5.1 Hypothesis 
Comparison of measured and reconstructed doses (based on TomoTherapy DVPA 
software) for head and neck, prostate and lung plans delivered to the TomoPhantom with and 
without intentional delivery errors will demonstrate: 
(a) agreement within 2% for a point in a high dose, low gradient region 
(b) a gamma index < 1 for 90% of the points within a selected two dimensional region 
 
     Treatment detector sinogram 
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1.5.2 Specific Aims 
1. Create three different TomoTherapy treatment plans on the TomoPhantom.  Generate plans 
using PTV and OAR contours extracted from clinical treatment plans for a head & neck 
(H&N), prostate and lung, and placed on the TomoPhantom.  Optimize plans using standard 
clinical protocols. 
2. Deliver, measure and extract the exit detector data for each plan 
a. multiple times on different days (to account for statistical fluctuation) 
b. with intentional adjustment to machine’s output 
c. with intentional leaf opening time error (to determine the significance of leaf opening 
time error within the set tolerance of the delivery system) 
3. Compute the reconstructed dose on DVPA software using the treatment detector sinogram. 
4. Compare the measured dose with the original planned dose and the reconstructed dose 












CHAPTER 2.  METHODS AND MATERIALS 
2.1 Aim 1:  Generate Treatment Plans 
2.1.1 TomoTherapy TomoPhantom 
Plans for this study were generated on the TomoTherapy-provided cylindrical 
measurement phantom, or TomoPhantom
TM
 (TomoTherapy Inc.) (Figure 6).  The two halves of 
the TomoPhantom combine to create a cylinder with dimensions of 30 cm in diameter and 18 cm 
in length.  The material of the homogeneous phantom consists of Virtual Water
TM
 with a density 




  Along one diameter on the side of the phantom, there are 28 6.3-mm 
diameter cylindrical slots aligned parallel to the cylinder axis and separated by 1 cm from their 
centers to allow for point dose measurements using ionization chambers (Figure 7).  There are 
virtual water plugs for the slots that don’t have a detector.  Relative dose distribution 
measurements may be achieved by placing a radiographic film between the 2 halves of the 
phantom. 
 
















Figure 7. Axial and sagittal (central cut) view of the TomoPhantom 
2.1.2 Scanning and Transferring the Image of the TomoPhantom 
The TomoPhantom was scanned on the GE Lightspeed RT CT scanner available at Mary 
Bird Perkins Cancer Center.  Orientation of the phantom was set such that the circular volume is 
in the axial plane with the cylindrical slots lined up vertically during scan.  The scanning 
parameters were set as the following: 
• Helical scan 
• 50 cm diameter field of view 
• 512×512 axial pixel resolution 
• 2.5 mm longitudinal spacing 
• 83 slices = 20.75 cm 
• 120 kVp beam energy 
After obtaining an image dataset of the TomoPhantom, the same image dataset was sent 
to the TomoTherapy Research TPS three separate times to create three different treatment plans.  
Each time, the name of the image dataset was changed to create and identify the three different 
plans (“DV STUDY – H/N”, “DV STUDY – PROSTATE” and “DV STUDY – LUNG”). 
Holes start 1 cm 
above center 




The image dataset was also sent once to Pinnacle
3
 TPS for the purpose of creating a 
structure set for each plan.  Since the phantom is not anthropomorphic, a virtual structure set for 
each plan was obtained by copying a patient’s structure set with disease sites corresponding to 
those studied here.  Figures 8 and 9 illustrate the copying of contours from a patient plan to the 
TomoPhantom for the lung case.  Figure 8 shows axial, coronal and sagittal slices through a 
patient’s CT dataset.  The target volume and critical structures have been contoured and are 
displayed by colored lines on the CT images.  The structure sets was copied to the phantom 
image dataset as seen in Figure 9. 
                      Axial               Coronal       Sagittal 
 
Figure 8. Contours of lung patient with target volume in red 
                        Axial               Coronal       Sagittal 
 




2.1.3 Treatment Planning 
Copying of the contours for each plan in Pinnacle
3
 TPS required adding a patient image 
dataset corresponding to the disease site into the plan’s list of images.  The patient’s image 
dataset was set as the secondary image while the TomoPhantom image dataset was set as the 
primary image.  Importing of the patient’s structure set was done separately within each plan and 
was assigned to the patient’s image dataset initially.  The patient’s image dataset (with the 
structure set) was then fused with the TomoPhantom image dataset.  This allowed displaying and 
shifting of the structure set position relative to the TomoPhantom.  The structure set was shifted 
such that the center of the target volume covered the active measurement volume of the 
ionization chamber (see Figure 9).  The structure set was then assigned to the TomoPhantom’s 
image dataset and exported to the TomoTherapy Research TPS. 
Image data that were imported into TomoTherapy Research TPS were down-sampled to 
256×256 axial pixel resolution.  Planning parameters (jaw size setting, pitch, prescription dose 
on PTVs and dose tolerances for OARs) for each plan used standard clinical protocols in use at 
MBPCC and are shown in Table 1.  Treatment delivery was set to 2 Gy per fraction to simulate 























copied contours from patient plans generated plans 
TomoTherapy Research TPS 
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Plans were optimized using beamlet mode with a modulation factor of 3.0 and 4.0 (see 
Table 1).  Settings for the importance of PTV were initially set 3 times more than the avoidance 
structures.  Penalties for all structures were initially set to 1.  The procedure used for adjusting 
penalties during optimization followed the standard recommended procedure from 
TomoTherapy.  Changes in penalties were made after every 12 iterations and to only those 
structures that did not yet meet the plan objectives as outline in Table 1.  The total number of 
iterations for each plan had approximately 120 iterations.  Although the plan quality was not of 
interest for this study, the final plans were made to resemble typical clinical plans.  Each plan 




2.2 Aim 2:  Delivery of Treatment Plans 
2.2.1   Measurement Setup 
Prior to the delivery of each plan, an MVCT scan was taken of the TomoPhantom to 
verify and adjust alignment, if necessary.  To prevent exposure to the film before the planned 
delivery, no film was placed in the phantom during scan.  Measurements were collected using an 
ionization chamber (Model A1SL Exradin Miniature Shonka Thimble Chamber), with a 
collecting volume of 0.057 cm
3
, placed in one of the cylindrical slots of the TomoPhantom and 
an Extended Dose Range 2 (EDR2) radiographic Kodak film placed in between the two halves of 
the phantom (Figure 11).  The electrometer (Keithley Model 614) used to take readings from the 
ionization chamber had a bias voltage setting of -300V with a maximum leakage rate of 0.01 
nC/minute. 
The prostate and lung plans were delivered with the phantom orientation as seen in 
Figure 10a.  For the H&N plan, the phantom was rotated 90° counterclockwise (Figure 10b) so 
that the ionization chamber could be within the plan’s PTV. 
 
      
(a)                                                                           (b) 




2.2.2   Treatment Delivery 
Each plan was delivered twice per day and repeated over several days to account for 
statistical fluctuations.  For each delivery, measurements for each plan consisted of two ion 
chamber readings and one film exposure.  The temperature and pressure were recorded at the 
time of measurements to correct for the ion chamber calibration value (PTP). 
Conversion of the ion chamber’s electrometer reading (Mraw) to measured dose (DM) 
followed the AAPM TG-51 protocol
20
 given by equation 2. 
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Pion: ion recombination correction 
 
PTP: temperature & pressure correction 
 
Pelec: electrometer calibration factor [C/reading] 
 
Ppol: chamber polarity effects 
 
kQ: beam quality conversion factor 
 
: ionization chamber calibration factor [Gy/C] 
Values of Pion (1.004) and Ppol (1.000) had previously been determined for this chamber 
following TG-51 protocol.  The value of kQ (0.996) was obtained using the procedure 
recommended by Thomas et al.
21
  The calibration factor for both the ionization chamber () 
and the electrometer (Pelec) had been obtained within the past 2 years from an Accredited 
Dosimetry Calibration Laboratory (ADCL). 
A calibration film was exposed on each day that measurements were made in order to 
convert the chemical response due to radiation exposure of the film to the dose deposited.  The 
calibration film consists of 8 rectangular regions that were exposed to a range of radiation 
exposures (Figure 12a)
22
 from a Varian 21EX linear accelerator using the same nominal beam 
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energy (6 MV) as the TomoTherapy Hi·Art delivery system.  The calibration film was placed at 
100 cm source-to-axis distance with 10 cm of buildup and 5 cm of backscatter using a Plastic 
Water phantom® (Computerized Imaging Reference Systems Inc., 2428 Almeda Ave. Suite 316, 
Norfolk, VA 23513).  A typical calibration curve is shown in Figure 12b. 
 
 (a)                                                         (b) 
Figure 12. (a) Scanned image of calibration film after exposure and processing and  
(b) a typical calibration curve 
 
The average optical density value within a small rectangular region (~3×3 cm) for each of 
the exposed area was obtained from the scanned image.  Dose delivered to the exposed area 
corresponds to a measured dose that had been made using an ionization chamber placed within 
the same region under the same setup.  All exposed films were processed 24 hours after delivery 
(due to variations in dose response within 1 hour of exposure)
23
 and were scanned using a Vidar 
DosimetryPro Advantage film digitizer (VIDAR Systems Corporation, 365 Herndon Parkway, 
Herndon, VA 20170).  The films were scanned with a resolution of 71 pixels per inch at 16 bit. 
In addition to the standard treatment deliveries, each plan was delivered with the output 
or leaf open times intentionally adjusted away from their baseline value.  Adjustments in output 
























console prior to delivery.  Pfn voltage settings were adjusted to vary the output by approximately 
0.5 - 4% per delivery in either directions.  Output variations of more than 4% will trigger an 
interlock and stop the delivery. 
Adjustments in leaf open times were made by modifying the leaf control sinogram files.  
A separate leaf control sinogram file is created for every scheduled treatment and is accessible in 
a patient plan archive.  In each patient’s archive folder, unique identifiers (UID) are given to 
most of the filenames in the archive directory (e.g., “1.2.826.01.3680043.2.200.2136569166.-
142.83541.763.sin”).  All UIDs are indexed within a single plan’s extensible markup language 
(xml) file, which is also located under the archive directory.  The xml file for each plan was 
opened using a text editor program (e.g., Notepad).  Within the xml file, the leaf control 
sinogram files UID were listed next to the tag “sinogramDataFile” associated with each date of 
planned treatment delivery.  These numbers were recorded in order to access the sinogram files 
for this study. 
For each patient plan, twelve leaf control sinogram files were modified.  A tracking 
record was kept that associated the modified file with the scheduled delivery date.  The file 
contained a matrix of Nproj by 64 floating point numbers ranging in value from 0 to 1.0, where 
Nproj is the number of projections for the treatment.  These data represent the fraction of time the 
leaves remain open for each projection.  The sinogram files were written in binary (little-endian) 
format and were read and byte swapped using a software program called “Transform” (version 
3.4, Fortner Software LLC).  The matrix data were then copied onto an Excel spreadsheet to 
modify the leaf open times. 
The time equivalent (∆t) for each matrix value was determined by multiplying the value 
by the projection period (equation 3).  The projection period was determined by dividing the 
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gantry period (given on the plan printout) by the number of projections per rotation (stated 
previously as 51). 
 !"#$%  ! &'!()*+,-./0123.4!,0-3.5!()*+  &'!()*+6789:;!<=:>?@!(ABCD+E!?F!<:?G=H9>?8I:?979>?8                         (3) 
The modified matrix data were byte swapped using in-house software, and then copied 
back onto the Transform program to save it with the proper file name extension.  With the 
modified leaf control sinogram files placed within the archived directory, the plans were 
retrieved back into the database of the TPS to allow for plan deliveries on the Hi·Art delivery 
system. 
The TomoTherapy Hi·Art delivery system gives a fault and stops treatment when leaf 
open time errors of ≥ 32 milliseconds (msec) for 4 instances are detected.  Intentional leaf open 
time errors were introduced which were close to but within these limits, in order to test the limits 
of the correction software.  The leaf open times were adjusted for all the leaves by approximately 
±10 and ±30 msec (actual adjustment time is dependent on the value from equation 3).  Then 
only the center leaf (since most tomotherapy treatments position the target at isocenter) or the 
leaf that contributes the most to the target was adjusted by approximately ±10 and ±30 msec to 
determine the effect on dose delivery.  For modified leaf open time values that are greater than 
1.0 or less than 0.0, we set them to 1.0 or 0.0 since values outside the range of 0 and 1 are not 
deliverable.   
2.3 Aim 3:  Dose Reconstruction Using Detector Data 
Treatment delivery data were immediately extracted after each delivery, since these data 
were erased whenever a new procedure was loaded for delivery.  The detector data contain signal 
information from the centrally located 640 (out of 738) xenon exit detectors and the three 
monitor chambers located between the x-ray source and MLC (Figure 13).  The data was 
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acquired for every pulse of the linac, which operates at a frequency of 300 pulses per second in 
treatment mode. 
 
Figure 13. Locations of monitor chambers and exit detectors 
The extracted detector data files were transferred to the TomoTherapy Research TPS.  
These data were read in by the DVPA software to determine the DV sinogram based on 
variations in machine output and/or leaf open times during treatment delivery.  The DVPA 
software is capable of creating a DV sinogram by considering either factor individually or 
combined.   
As described in section 1.4.2, the DVPA software scales each measured leaf open time by 
the percent difference between measured and planned beam output over the period of the 
projection.  At the time of the initial beam commissioning, output was adjusted to deliver 900 
cGy per minute for a static beam of 40 × 6 cm field size, to a depth of 1.5 cm at the isocenter of 
the machine.  After this adjustment was complete, the average digital signal/pulse of each 
monitor chamber (MU1) was stored on the DVPA software.  The current value for MU1 on the 









at any projection is found by multiplying this value by the number of pulses the leaf was opened.  
The measured output is obtained by summing the counts from MU1 over the same pulses. 
If variations in leaf open time relative to the planned treatment are considered in 
determining the DV sinogram, then the FWHM of the exit detector array signal is used to 
determine the actual leaf open time.  At 300 pulses per second, the time between pulses is 
approximately 3 msec, which is small compared to typical leaf open times of 200 msec from 
planned treatment deliveries studied in this work. 
Figures 14a, 14b and 15 are screenshots from the DVPA software program which display 
sample DV sinograms using each factor individually and the combined factors, respectively.  
The three sinograms represents partial view of the leaf control sinogram for the planned, 
reconstructed (DV sinogram) and their difference.  The horizontal axis is the leaf number and the 
vertical axis is the projection number.  Each cycle in the sinogram represents one rotation of the 
gantry.  Each point in the sinogram matrix represents leaf open time for a specific leaf in unit of 
second with the brighter colors having longer open times (red being the longest and black 
meaning closed leaf).  The machine output during delivery, determined from the monitor 
chamber data, is shown as the oscillating purple line. 
For all three figures, locations of the crosshair are the same to show how DVPA account 
variations in machine output and leaf open time separately and their combined contribution to the 
final DV sinogram.  The verification histogram on the right side of Figures 14 and 15 shows the 
leaf open time differences for fraction of active leaf states.  Notice how variations in leaf open 
time contribute to differences between the planned and reconstructed sinograms more so than 







Figure 14. Comparison of the planned sinogram and reconstructed sinogram based on 




Figure 15. Comparison of the planned sinogram and reconstructed sinogram based on 
both leaf opening time and machine output. 
 
DR in the DVPA software is computed based on a leaf control sinogram and an image 
dataset.  For leaf control sinogram, DVPA allows the option to either use the planned or DV 
sinogram.  For the image dataset, DVPA allows the option to either use the planned/reference 
image dataset or to use an MVCT image dataset taken immediately prior to treatment.  If an 
MVCT image dataset is chosen, then a different IVDT is required, since the relationship between 
CT number and density is changed.  Although this is beneficial for a patient with daily setup 
changes, it is not required for a phantom.  Therefore, all reconstructed doses for this study were 
computed using the reference image and the corresponding DV sinogram with the dose grid set 
to fine.  The reference image dataset was chosen over the MVCT image dataset to omit any 




To confirm that the dose algorithm in DVPA is the same as the TPS, a DR was computed 
on the unmodified H&N plan using the reference image and the planned sinogram.  The result 
showed that there was no difference in the dose distribution between the planned and 
reconstructed. 
2.4 Aim 4:  Dose Comparison of Measurements Versus Reconstructed 
After DVPA dose reconstruction calculations were performed, the calculated point doses 
(at the location of the ion chamber) and the planar dose distributions (at the location of the film 
plane) were extracted from the system for comparison with measurement results.  These 
comparisons were made using the quality assurance tools available on the DVPA software and 
on the planning station application on the TomoTherapy Research TPS. 
The calculated point doses used in comparing with the measured data were chosen to be 
at the center of the ion chamber’s active volume.  The dose grid point in the calculated dose 
matrix closest to this location was selected.  In the DVPA software, point dose values from the 
planned and reconstructed dose distributions are displayed to the thousandth decimal and are in 
units of gray. 
Standard deviations for both the measured and calculated point doses were determined 
using equation 4.  If both the measured or calculated dose for each scheduled delivery have the 
exact same value, then the standard deviation was set to half of the last significant digit (e.g., 
2.07 Gy will have σ = ±0.005). 
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Calculation for the differences between measured and reconstructed doses used equation 
5.  The sum of their standard deviations is taken as the square root of the sum of their square 
(equation 6). 
T!  !UVWU                                                                 (5) 
J*X) !YJ)R Z JR                                                           (6) 
Evaluation of the film measurements were done within the TomoTherapy Research TPS.  
It provides a Delivery Quality Assurance (DQA) analysis tool where the DQA plan and 
measured dose distributions are overlaid for comparisons in one dimension (dose profiles) and/or 
two dimensions (isodose or gamma index distributions).  The DQA plan simulates the planned 
treatment on a measurement phantom for dose delivery verification.  Dose in the DQA plan 
contains the composite dose from all treatment fractions.  In order to compare film 
measurements with the reconstructed dose distributions computed by DVPA, a DQA plan was 
created for each patient plan.  The dose file created in the DQA plan was then replaced with a 
reconstructed dose file. 
Reconstructed dose files have an “.img” filename extension and are the same dimension 
and file size as the planned and DQA dose files.  All dose files are accessible under the patient 
archive directory.  Identifying a reconstructed dose file to the corresponding treatment delivery 
was done by associating the date and time it was computed on the DVPA planning system to the 
date and time that is associated with a filename within the xml file.  The same was done for the 
DQA dose file. 
Before replacing the DQA dose file with a reconstructed dose file, each reconstructed 
dose was scaled up by a factor equal to the total number of fractions for the planned treatment.  
This is due to the fact that the DQA analysis tool scales the calculated dose down to one fraction 
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for comparison with the measured data (film), which were measured from a single fraction 
delivery.  Replacement of the DQA dose file with the reconstructed dose file was made by 
renaming the reconstructed dose file to the DQA’s filename.  The archive was then retrieved 
back into the TomoTherapy Research TPS.  This step was repeated for every reconstructed dose 
used to compare with the corresponding measured film data. 
Film dosimetry evaluation for this study uses a technique that gives a quantitative 
analysis of the dose distributions between measured and computed data, also known as gamma 
index distibution.
24
  This technique is a composition of two types of comparisons:  1) dose 
difference in regions of low dose gradient and 2) distance-to-agreement (DTA) in region of high 
dose gradients.  The latter is used because small spatial error in high dose gradient regions could 
result in large dose difference.  Determination of a pass or fail gamma index is dependent on the 
conditions set in the parameters for dose difference and DTA tolerances.  Independent of the 
conditions, a gamma index of ≤ 1 is considered passing using equation 7.  Figure 16 is a 
graphical illustration of the gamma index that visually defines the variables used in equations 7 
and 8.  The surface of the elliptical sphere, which is dependent on the values of the dose 
difference and the DTA tolerances, represents a gamma value of 1. 
[O)Q  \]^!_ΓO) Q`a_`                                               (7) 
where                                           ΓO) Q  KbOADQ&cUb Z
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&Ub                                               (8) 
r: distance between rm and rc                            
rm: measured point                                             
rc: calculated point                              
δ:      dose difference between doses at rm and rc 
dM:     DTA tolerance 
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DM:    dose tolerance 
 
Figure 16. Graphical illustration of the gamma index distribution 
This study uses TomoTherapy Planning Station Alpha6, which provides a histogram of 
the gamma index within a selected region of interest.  A maximum region of interest was chosen 
while keeping the borders at least 2 cm from the phantom edges to avoid markings on the edge of 
the film used for registration.  The regions selected for all film analysis of the same study were 
consistent to within 0.5 mm (see Figure 17).  The standard conditions used for the gamma index 
were:   dM = 3 mm, DM = 3% of max dose. 
Analysis of film measurements were made after scaling the film dose distributions based 
on the ionization chamber measurements.  It was assumed that the ratio of doses to an arbitrary 
point on the film (Dfilm) to the ion chamber (Dic) should be the same for the measurement (m) and 
the reconstructed (r) plan.  The film point was selected to be in a low dose gradient region, as 
close as possible to the ion chamber point.  The film dose was scaled by the following scaling 
factor: 
ef#gh!ifj  ! kDAlkmAA n
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Figure 17. Displays a screenshot of the film analysis program of the 
TomoTherapy TPS.  Shown are isodose lines from computed (solid) 
and measured (dash) dose distributions overlaid on a reconstructed 
coronal slice of the measurement phantom.  The yellow rectangle 











CHAPTER 3.  RESULTS AND DISCUSSION 
3.1 Aim 1:  Generate Treatment Plans 
Contours for each of the three plans were copied from a patient plan that corresponded to 
their treatment site.  Treatment planning parameters were set to simulate typical patient plans 
using standard clinical protocols in use at MBPCC.  Figures 18, 20 and 22 show the optimized 
dose distributions from three different views (axial, coronal and sagittal) of the H&N, prostate 
and lung plans, respectively.  Figures 19, 21 and 23 show the dose volume histograms (DVH) of 
the H&N, prostate and lung plans, respectively.  Despite being optimized on a cylindrical 
phantom, the dose distributions for each plan are similar to clinical plan results.  Dose within the 
PTVs have a high dose/low gradient which help reduce errors associated with misalignment of 
ionization chamber during measurements.  Dose to the critical structures for the three plans are 
below standard clinical tolerances. 
Since all plans simulated those of clinical patient plans, parameters which affect delivery 
errors (gantry rotational speed, couch speed and leaf opening time) are likely to be close to 
clinical values.  All plans were also fractionated so that each treatment delivery will deliver a 
dose of 2 Gy to the PTV. 
                     Axial           Coronal             Sagittal 
 




Figure 19.  DVH of the H&N plan 
                     Axial           Coronal             Sagittal 
 
Figure 20. Dose distribution of the prostate plan 
 










                     Axial           Coronal             Sagittal 
 
Figure 22. Dose distribution of the lung plan 
 
Figure 23. DVH of the lung plan 
3.2 Aim 2:  Delivery and Measurements of Treatment Plans 
Measured data from the delivery of the H&N, prostate and lung plans are shown in 
Tables 2, 3 and 4, respectively.  Film data are not shown here but will be discuss in section 3.4.2.  
The planned dose at the point of measurement for the H&N, prostate and lung plans are 2.037 
Gy, 2.063 Gy and 2.022 Gy, respectively.  Each delivery procedure was measured twice per day 
and is separated in the tables by highlights.  Temperature and pressure readings were taken at the 
end of each delivery.  The calibration factors of the electrometer and ion chamber were also 






Deliveries made with intentional offsets to the output are labeled as ‘∆pfn’ along with the 
voltage difference from the machine’s current value.  Calculations for the measured dose used 
Equation 2 (c.f., section 2.2.2). 
 
















Normal - Day 1 0.384 23.8 765.0 9.87E-09 5.468E+08 2.071 
Normal - Day 1 0.383 23.8 765.0 9.87E-09 5.468E+08 2.066 
Normal - Day 2 0.380 23.9 763.0 9.87E-09 5.468E+08 2.056 
Normal - Day 2 0.380 23.9 763.0 9.87E-09 5.468E+08 2.056 
Normal - Day 3 0.383 23.4 756.3 9.87E-09 5.468E+08 2.087 
Normal - Day 3 0.383 23.4 756.3 9.87E-09 5.468E+08 2.087 
Normal - Day 4 0.381 23.3 769.5 9.87E-09 5.468E+08 2.040 
Normal - Day 4 0.381 23.3 769.5 9.87E-09 5.468E+08 2.040 
Normal - Day 5 0.378 23.9 770.0 9.87E-09 5.468E+08 2.027 
Normal - Day 5 0.379 24.1 770.0 9.87E-09 5.468E+08 2.033 
Normal - Day 6 0.368 24.1 761.0 1.004E-08 5.468E+08 2.032 
Normal - Day 6 0.369 24.0 761.0 1.004E-08 5.468E+08 2.037 
Normal - Day 7 0.372 24.6 763.0 1.004E-08 5.468E+08 2.052 
Normal - Day 7 0.372 25.0 763.0 1.004E-08 5.468E+08 2.055 
All leaves -10 ms 0.351 23.9 763.0 9.87E-09 5.468E+08 1.899 
All leaves -10 ms 0.350 23.9 763.0 9.87E-09 5.468E+08 1.894 
All leaves +10 ms 0.410 24.4 763.0 9.87E-09 5.468E+08 2.222 
All leaves +10 ms 0.410 24.4 763.0 9.87E-09 5.468E+08 2.222 
All leaves -30 ms 0.296 24.3 763.0 1.004E-08 5.468E+08 1.631 
All leaves -30 ms 0.295 24.8 763.0 1.004E-08 5.468E+08 1.628 
All leaves +30 ms 0.449 24.8 763.0 1.004E-08 5.468E+08 2.479 
All leaves +30 ms 0.451 24.6 763.0 1.004E-08 5.468E+08 2.488 
Leaf #27 -10 ms 0.381 24.5 763.0 9.87E-09 5.468E+08 2.065 
Leaf #27 -10 ms 0.381 24.5 763.0 9.87E-09 5.468E+08 2.065 
Leaf #27 +10 ms 0.384 24.6 762.0 9.87E-09 5.468E+08 2.085 
Leaf #27 +10 ms 0.384 24.6 762.0 9.87E-09 5.468E+08 2.085 
 Leaf #33 -10 ms 0.382 24.6 762.0 9.87E-09 5.468E+08 2.070 
Leaf #33 -10 ms 0.382 24.6 762.0 9.87E-09 5.468E+08 2.070 
Leaf #33 +10 ms 0.384 24.6 761.0 9.87E-09 5.468E+08 2.088 
Leaf #33 +10 ms 0.384 24.6 761.0 9.87E-09 5.468E+08 2.088 
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Normal - Day 1 0.380 23.5 761.0 9.87E-09 5.468E+08 2.059 
Normal - Day 1 0.380 23.8 761.0 9.87E-09 5.468E+08 2.061 
Normal - Day 2 0.379 23.7 758.0 9.87E-09 5.468E+08 2.063 
Normal - Day 2 0.378 23.8 758.0 9.87E-09 5.468E+08 2.059 
Normal - Day 3 0.378 24.3 755.0 9.87E-09 5.468E+08 2.070 
Normal - Day 3 0.378 24.5 755.0 9.87E-09 5.468E+08 2.071 
Normal - Day 4 0.375 24.1 754.5 9.87E-09 5.468E+08 2.050 
Normal - Day 4 0.375 24.2 754.5 9.87E-09 5.468E+08 2.051 
Normal - Day 5 0.380 24.5 761.0 9.87E-09 5.468E+08 2.065 
Normal - Day 5 0.380 24.5 761.0 9.87E-09 5.468E+08 2.065 
Normal - Day 6 0.371 24.0 761.0 1.004E-08 5.468E+08 2.048 
Normal - Day 7 0.370 24.2 761.0 1.004E-08 5.468E+08 2.044 
Normal - Day 7 0.373 23.6 762.0 1.004E-08 5.468E+08 2.053 
Normal - Day 7 0.373 23.8 762.0 1.004E-08 5.468E+08 2.055 
All leaves -10 ms 0.352 24.0 761.0 9.87E-09 5.468E+08 1.908 
All leaves -10 ms 0.352 23.8 761.0 9.87E-09 5.468E+08 1.908 
All leaves +10 ms 0.406 23.8 761.0 9.87E-09 5.468E+08 2.202 
All leaves +10 ms 0.406 23.8 761.0 9.87E-09 5.468E+08 2.202 
All leaves -30 ms 0.294 23.8 758.0 9.87E-09 5.468E+08 1.601 
All leaves -30 ms 0.294 23.9 758.0 9.87E-09 5.468E+08 1.601 
All leaves +30 ms 0.458 23.9 758.0 9.87E-09 5.468E+08 2.494 
All leaves +30 ms 0.458 23.9 757.5 9.87E-09 5.468E+08 2.508 
Leaf #33 -10 ms 0.367 24.3 755.0 9.87E-09 5.468E+08 2.009 
Leaf #33 -10 ms 0.368 24.3 755.0 9.87E-09 5.468E+08 2.015 
Leaf #33 +10 ms 0.386 24.3 755.0 9.87E-09 5.468E+08 2.113 
Leaf #33 +10 ms 0.383 24.8 755.0 9.87E-09 5.468E+08 2.102 
Leaf #33 -30 ms 0.350 24.5 761.0 9.87E-09 5.468E+08 1.902 
Leaf #33 -30 ms 0.350 24.5 761.0 9.87E-09 5.468E+08 1.902 
Leaf #33 +30 ms 0.406 24.7 761.0 9.87E-09 5.468E+08 2.208 
Leaf #33 +30 ms 0.406 24.7 761.0 9.87E-09 5.468E+08 2.208 
∆pfn:  +0.01 V 0.383 24.4 762.0 9.87E-09 5.468E+08 2.078 
∆pfn:  +0.01 V 0.383 24.4 762.0 9.87E-09 5.468E+08 2.078 
∆pfn:  +0.02 V 0.385 24.5 761.5 9.87E-09 5.468E+08 2.091 
∆pfn:  +0.04 V 0.389 24.5 761.5 9.87E-09 5.468E+08 2.113 
∆pfn:  +0.07 V 0.388 23.9 761.0 1.004E-08 5.468E+08 2.141 
∆pfn:  +0.07 V 0.389 24.2 761.0 1.004E-08 5.468E+08 2.149 
∆pfn:  -0.07 V 0.356 23.9 761.0 1.004E-08 5.468E+08 1.964 
∆pfn:  -0.07 V 0.354 24.2 761.0 1.004E-08 5.468E+08 1.955 
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Table 4. Ion chamber measurements for the lung plan (planned dose = 2.022 Gy) 
 
The measurement results in Tables 2-4 show a wide range of point doses measured near 
the center of the target volume of each plan.  The top portion of each table displays results for 
treatment plans delivered without any intentional variation in output or leaf open time.  In 
general, these data show little to no variation between doses measured on the same day, although 












Normal - Day 1 0.363 24.4 761.0 9.87E-09 5.468E+08 1.972 
Normal - Day 1 0.364 24.4 761.0 9.87E-09 5.468E+08 1.978 
Normal - Day 2 0.363 23.6 761.0 9.87E-09 5.468E+08 1.967 
Normal - Day 2 0.363 24.3 761.0 9.87E-09 5.468E+08 1.972 
Normal - Day 3 0.357 23.8 761.0 1.004E-08 5.468E+08 1.969 
Normal - Day 3 0.357 23.7 761.0 1.004E-08 5.468E+08 1.969 
Normal - Day 4 0.358 23.8 762.0 1.004E-08 5.468E+08 1.972 
Normal - Day 4 0.358 23.8 762.0 1.004E-08 5.468E+08 1.972 
Normal - Day 5 0.353 24.6 762.0 1.004E-08 5.468E+08 1.950 
Normal - Day 5 0.353 24.8 762.0 1.004E-08 5.468E+08 1.951 
All leaves -10ms 0.339 24.6 761.0 9.87E-09 5.468E+08 1.843 
All leaves -10ms 0.339 24.6 761.0 9.87E-09 5.468E+08 1.843 
All leaves +10 ms 0.389 24.8 761.0 9.87E-09 5.468E+08 2.117 
All leaves +10 ms 0.389 24.8 761.0 9.87E-09 5.468E+08 2.117 
All leaves -30 ms 0.289 24.8 762.0 9.87E-09 5.468E+08 1.570 
All leaves -30 ms 0.289 24.8 762.0 9.87E-09 5.468E+08 1.570 
All leaves +30 ms 0.439 24.8 762.0 9.87E-09 5.468E+08 2.385 
All leaves +30 ms 0.439 24.8 762.0 9.87E-09 5.468E+08 2.385 
Leaf #32/33 -10 ms 0.343 24.2 761.0 9.87E-09 5.468E+08 1.862 
Leaf #32/33 -10 ms 0.343 24.2 760.5 9.87E-09 5.468E+08 1.864 
Leaf #32/33 +10 ms 0.384 24.3 760.0 9.87E-09 5.468E+08 2.089 
Leaf #32/33 +10 ms 0.384 24.2 760.0 9.87E-09 5.468E+08 2.088 
Leaf #32/33 -30 ms 0.299 24.3 760.0 9.87E-09 5.468E+08 1.626 
Leaf #32/33 -30 ms 0.298 24.3 760.0 9.87E-09 5.468E+08 1.621 
Leaf #32/33 +30 ms 0.429 24.4 760.0 9.87E-09 5.468E+08 2.334 
Leaf #32/33 +30 ms 0.428 24.2 760.0 9.87E-09 5.468E+08 2.327 
∆pfn:  -0.05 V 0.351 24.3 760.0 9.87E-09 5.468E+08 1.909 
∆pfn:  -0.05 V 0.350 24.3 760.0 9.87E-09 5.468E+08 1.904 
∆pfn:  +0.05 V 0.373 24.0 760.0 9.87E-09 5.468E+08 2.027 
∆pfn:  +0.05 V 0.373 24.2 760.0 9.87E-09 5.468E+08 2.028 
∆pfn:  -0.07 V 0.340 24.3 761.0 1.004E-08 5.468E+08 1.879 
∆pfn:  -0.07 V 0.341 23.9 761.0 1.004E-08 5.468E+08 1.882 
∆pfn:  +0.07 V 0.374 24.1 761.0 1.004E-08 5.468E+08 2.065 
∆pfn:  +0.07 V 0.373 24.1 761.0 1.004E-08 5.468E+08 2.060 
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small differences are seen between doses measured on different days.  The minimum and 
maximum measured doses ranged from (2.03, 2.09) Gy, or (-0.3%, +2.6%) of the planned dose, 
for the H&N plan; (2.05, 2.07) Gy, or (-0.6%, +0.3%) for the prostate plan, and (1.95, 1.98) Gy, 
or (-3.6%, -2.1%) for the lung plan.  The lung plan had the worst agreement when comparing 
with the planned dose, although the overall agreement was still within 4%. 
The measurement results for leaf open time changes in Tables 2-4 show the largest 
variation in doses from the planned doses.  Results are displayed for a constant increase in all 
leaf open times for all projections for both an individual leaf, and all 64 leaves.  As expected, the 
differences were largest when all leaf open times were intentionally adjusted by 30 msec.  The 
variation seen for these cases were (-20.0%, +22.2%) for H&N plan, (-22.4%, +21.2%) for the 
prostate plan, and (-22.4%, +18.2%) for the lung plan.   
The magnitude of the changes for the adjustment of one or two leaf open times varied 
according to treatment plan.  For the H&N plan, where either leaf number 27 or 33 were 
adjusted, the measured doses ranged from (2.07, 2.09) Gy, or (+1.6%, +2.6%) above the plan 
dose.  For the prostate plan, a larger variation was seen when leaf number 33 was adjusted by the 
same amount, with measured doses ranging from (2.01, 2.11) Gy, or (-2.6%, +2.3%) above the 
plan dose.  This difference may be due to the fact that the H&N target and measurement point 
are located further away from the tomotherapy axis or rotation, so that individual leaves 
contribute to the dose at this point for a few projections only.  In the H&N case, the measurement 
was made 4 cm from the axis, while the lung and prostate doses were measured 0.5 cm from the 
axis.  For the lung plan, the two leaves centered on the central axis (number 32 and 33) were 
varied by both 10 and 30 msec.  In this case the variation in measured dose was larger, ranging 
from (1.86, 2.09) Gy, or (-8.0%, +3.4%). 
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The intentional changes made to the leaf open times were much larger than those seen in 
a typical treatment delivery (c.f., Figure 14 from Chapter 2).  Nevertheless, these changes test the 
accuracy of the DVPA program under extreme conditions. 
Linac output rates were adjusted for both the lung and prostate treatment deliveries by 
adjusting the pfn voltage up to ±0.07 volts.  These results are also displayed in Tables 3 and 4.  
In these cases, the measured doses scaled proportional to the pfn voltage, with a slope of 
approximately 0.65% per unit change in pfn (1 cV).  Larger changes in pfn voltage setting (i.e., 
±0.08 volts) resulted in the machine interlock. 
3.3 Aim 3:  Dose Reconstruction Using Detector Data 
3.3.1 H&N Plan 
Reconstructed doses computed on DVPA use the DV sinogram and the reference image.  
Figures 24a, 24b and 24c shows the reconstructed (dashed) and planned (solid) isodose lines of 
the H&N study for the planned, +10 msec offset to center leaf and +10 msec offset to all leaves 
deliveries, respectively.  Figures 25a, 25b and 25c are the corresponding DVHs.  As expected, 
the reconstructed dose from planned delivery of the H&N study matched well with the planned 
dose (Figures 24a and 25a).  However, a slight difference in the dose delivered (~2%) is seen in 
Figures 24b and 25b due to placing a +10 msec offset to the center leaf for the entire delivery.  
The reconstructed isodose lines cover a larger volume relative to the planned isodose lines.  
Adjusting all leaves by +10 msec caused a larger increase in the dose delivered by approximately 
8% (Figures 24c and 25c). 
Note that Figures 24-25 displays only a portion of the delivered plans made in this study 









Figure 24. Isodose [Gy] overlay of the planned (solid) and reconstructed (dashed) for  
(a) planned delivery, (b) +10 msec offset to center leaf delivery and (c) +10 









Figure 25. DVH comparison between the planned (solid) and reconstructed (dashed) 
for (a) planned delivery, (b) +10 msec offset to center leaf delivery and     






3.3.2 Prostate Plan 
For the prostate study, isodose lines of a reconstructed dose from a planned delivery 
matched the planned isodose lines (Figure 26a) with their DVHs showing no significant 
difference (Figure 27a).  The delivery with an intentional offset to the center leaf by +30 msec 
led to an overdose along the central axis of the phantom which is depicted in Figure 26b.  Figure 
27b displays the corresponding PTV, which was located about the central axis of the machine, 
receiving an overdose for a portion of its volume.  Delivery with a +30 msec offset to all leaves 
caused an increase in the overall dose delivered by approximately +20% (Figures 26c and 27c).  
Delivery with a machine output offset of 0.7 V to the pfn (approx. +3.9%) yield to a delivered 
dose of approximately +4% (Figures 26d and 27d), as expected. 
Not all reconstructed doses for the prostate plan are shown, but the results for each agreed 
accordingly with the different offsets applied to the delivery. 
 
         Axial                                                             Sagittal 
                                     
 
Figure 26. Isodose [Gy] overlay of the planned (solid) and reconstructed (dashed) for 
(a) planned delivery, (b) +30 msec offset to center leaf delivery, (c) +30 
msec offset to all leaves delivery and (d) +0.7 V to the pfn delivery from the 
prostate study 

















Figure 27. DVH comparison between the planned (solid) and reconstructed (dashed) 
for (a) planned delivery, (b) +30 msec offset to center leaf delivery, (c) +30 
msec offset to all leaves delivery and (d) +0.7 V to the pfn offset delivery 








Figure 27 (continued). 
 
 
3.3.3 Lung Plan 
For the lung study, isodose lines of the reconstructed dose from a planned delivery 
matched the planned isodose lines (Figure 28a) with their DVHs having small differences 
(Figure 29a).  The delivery with an intentional center leaf offset of -30 msec led to a decrease in 
dose throughout the phantom and especially along the central axis of the phantom (Figure 28b).  
Compared to the prostate delivery with an intentional center leaf offset of +30 msec, this delivery 
has a greater effect in the delivered dose due to the PTV having a smaller volume.  Therefore, 
leaf open time errors have a greater contribution to the delivered dose of smaller PTV than to a 
larger PTV.  This is shown when comparing the DVHs of Figures 27b and 29b.  For the delivery 
with an intentional leaf open time offset of -30 msec to all leaves, the delivered dose to the PTV 









Figure 28. Isodose [Gy] overlay of the planned (solid) and reconstructed (dashed) for 
(a) planned delivery, (b) -30 msec offset to center leaf delivery and (c) -30 










Figure 29. DVH comparison between the planned (solid) and reconstructed (dashed) 
for (a) planned delivery, (b) -30 msec offset to center leaf delivery and (c) -






3.4 Aim 4:  Comparison of the Measured Dose Versus Reconstructed Dose 
3.4.1 Point Dose Comparison 
Daily ion chamber measurements for each plan consisted of two readings.  The readings 
on any given day varied little, and their average value was used for comparison with the model.  
Comparisons between the average measured dose and average reconstructed (DV) dose from 
deliveries with no intentional offset of the H&N, prostate and lung plans are shown in Tables 5, 
6 and 7, respectively.   
Table 5. Point dose comparison between the measured and the DV dose from DVPA 
for the H&N plan with no offset (planned dose = 2.037 Gy) 
 
 
Table 6. Point dose comparison between the measured and the DV dose from DVPA 






Avg DV Dose 
[Gy] 
Diff. 
Normal - Day 1 2.068 2.075 0.3% 
Normal - Day 2 2.056 2.058 0.1% 
Normal - Day 3 2.087 2.083 -0.2% 
Normal - Day 4 2.040 2.040 0.0% 
Normal - Day 5 2.030 2.033 0.1% 





Avg DV Dose 
[Gy] 
Diff. 
Normal  - Day 1 2.060 2.032 -1.4% 
Normal  - Day 2 2.061 2.039 -1.0% 
Normal  - Day 3 2.071 2.044 -1.3% 
Normal  - Day 4 2.051 2.026 -1.2% 
Normal  - Day 5 2.065 2.054 -0.5% 
Normal  - Day 6 2.046 2.051 0.2% 
Normal  - Day 7 2.054 2.069 0.7% 
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Table 7. Point dose comparison between the measured and the DV dose from DVPA 
for the prostate plan with no offset (planned dose = 2.022 Gy) 
 
 
The results show agreement between the DVPA model and the measured dose to within 
2% for all cases studied.  The slightly lower dose measured for the lung treatment plan was also 
reproduced by the DVPA software in Table 8. 
Table 8. Summary of the mean differences and their standard deviation over all 
measurements delivered with no intentional offset for each plan 
 
Plan 
Mean          
Diff. (%) 
± σ 
H&N 0.12 ± 0.34 
Prostate -0.64 ± 0.82 
Lung 0.08 ± 1.66 
 
Figures 30 through 32 displays the statistical variations and comparisons of the measured 
and reconstructed point dose data relative to the planned point dose for all plans. 
Comparisons between measured and reconstructed doses for deliveries with intentional 
leaf open time errors are shown in Tables 9, 10 and 11.  The results show that the DVPA is able 
to predict the delivered dose to within 2% for all three plans that had variable leaf open time 





Avg DV Dose 
[Gy] 
Diff. 
Normal  - Day 1 1.975 1.958 -0.9% 
Normal  - Day 2 1.970 1.954 -0.8% 
Normal  - Day 3 1.969 1.973 0.2% 
Normal  - Day 4 1.972 1.990 0.9% 
Normal  - Day 5 1.951 1.970 1.0% 
 
Figure 30. Statistical variations of 
with no intentional offset in the deliveries for the H&N plan
 
Figure 31. Statistical variations of the measured and reconstructed doses (DV dose) 





























the measured and reconstructed doses (DV
 















Figure 32. Statistical variations of the measured and reconstructed doses (DV dose) 




Table 9. Point dose comparison between the measured and the re
from DVPA for the H&N plan with intentional leaf open time offset (planned 













Delivered Plan             
(H&N) 
Avg Measured 
All leaves -10 ms 
All leaves +10 ms 
All leaves -30 ms 
All leaves +30 ms 
Leaf #27 -10 ms 
Leaf #27 +10 ms 































Table 10. Point dose comparison between the measured and the reconstructed dose 
from DVPA for the prostate plan with intentional leaf open time offset 
(planned dose = 2.063 Gy) 
 
 
Table 11. Point dose comparison between the measured and the reconstructed dose 
from DVPA for the lung plan with intentional leaf open time offset (planned 
dose = 2.022 Gy) 
 
 




Avg DV Dose 
[Gy] 
Diff. 
All leaves -10 ms 1.91 1.882 -1.5% 
All leaves +10 ms 2.20 2.177 -1.1% 
All leaves -30 ms 1.60 1.582 -1.1% 
All leaves +30 ms 2.50 2.471 -1.0% 
Leaf #33 -10 ms 2.01 1.983 -1.4% 
Leaf #33 +10 ms 2.11 2.101 -0.2% 
Leaf #33 -30 ms 1.90 1.860 -2.1% 
Leaf #33 +30 ms 2.21 2.226 0.7% 




Avg DV Dose 
[Gy] 
Diff. 
All leaves -10 ms 1.84 1.832 -0.4% 
All leaves +10 ms 2.12 2.098 -1.0% 
All leaves -30 ms 1.57 1.567 -0.2% 
All leaves +30 ms 2.39 2.367 -1.0% 
Leaf #32-33 -10ms 1.86 1.846 -0.8% 
Leaf #32-33 +10ms 2.09 2.076 -0.7% 
Leaf #32-33 -30ms 1.63 1.599 -1.6% 
Leaf #32-33 +30ms 2.33 2.312 -0.8% 
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Table 12 summarizes the range of dose differences of each plan for intentional leaf open 
time offsets deliveries versus its reconstructed dose. 
Table 12. Summary of the mean differences and their standard deviation over all 
measurements delivered with intentional leaf open time offset for each plan  
 
Plan 
Mean          
Diff. (%) 
± σ 
H&N 0.12 ± 0.34 
Prostate -0.64 ± 0.82 
Lung 0.08 ± 1.66 
 
Comparisons between measured and reconstructed doses for deliveries with intentional 
output errors are shown in Table 13 and 14.   
Table 13. Point dose comparison between the measured and the reconstructed dose 
from DVPA for the prostate plan with intentional output offset (planned dose 
= 2.063 Gy) 
 
 







Output +0.6% 2.08 2.072 -0.4% 
Output +1.1% 2.09 2.085 -0.2% 
Output +2.2% 2.11 2.097 -0.6% 
Output +3.9% 2.15 2.127 -0.9% 
Output -3.9% 1.96 1.969 0.4% 
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Table 14. Point dose comparison between the measured and the reconstructed dose 
from DVPA for the prostate plan with intentional output offset (planned dose 
= 2.022 Gy) 
 
 
3.4.2 Dose Distribution Comparison 
Quantitative comparisons of distributions between calculated and measured film doses 
was achieved using the gamma statistic
24 
computed on the TomoTherapy TPS Alpha6.  Fifty-six 
films were digitized, converted to dose and read into the TPS in this study.  Figure 33a display 
the gamma between the measured film dose and computed planned dose for a H&N planned 
delivery.  The grayscale shows the background of the film and the color-wash represents the 
gamma index.  Figure 33b is an isodose overlay in unit of Gy for the same dose distributions, 
where the solid lines represent film dose and the dashed represent planned dose.  Figure 34 
displays the profiles of the film and planned doses taken along the white crosshair in Figure 33a.  
Comparison between the film and reconstructed dose for the same H&N planned delivery is 
shown in Figure 35.  Refer to Appendix A, Appendix B and Appendix C for additional dose 
distribution comparisons of the H&N, prostate and lung study, respectively. 
For each film, a gamma distribution histogram was computed for all points contained 
within the selected region of interest.  An example of the histogram is shown in Figure 37, which 
displays the computed cumulative gamma distribution.  This graph plots the percentage of dose 







Output -2.7% 1.91 1.901 -0.2% 
Output +2.7% 2.03 2.007 -1.1% 
Output +3.9% 2.07 2.048 -0.8% 
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points within the selected region (y-axis) which exceed a given gamma value (x-axis).  An ideal 
cumulative histogram would have 100% at a gamma of 0, with 0% for all other points.  In Figure 
37, the percentage of points which fail the given criteria (i.e., γ < 1) is seen to be about 2% from 
the graph.  Since the TomoTherapy TPS did not have the ability to export the gamma 
distribution, important points on the curve were recorded for each comparison.  In addition to the 
percentage of points passing the criteria, the gamma index for which 90% and 95% of the 
measured points selected were recorded in order to get a sense of the shape of the curve in Figure 
37 without having to display a figure for every gamma distribution. 
Tables 15, 16 and 17 contain data that were taken from gamma distribution histograms of 
the H&N, prostate and lung plans, respectively.  In general, the tables show that the DVPA 
software accurately predicts the dose distribution both for unmodified and modified deliveries.  
The percentage of points which pass the criteria exceeds 96% for all measured plans for both the 
H&N and lung deliveries.  The agreements for the prostate treatment plan deliveries were not as 











      
(a)                                                                                (b) 
 
Figure 33. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
(dashed) doses from the H&N plan delivery with no intentional offset 
 
VERTICAL DOSE PROFILE                         HORIZONTAL DOSE PROFILE 
   
Figure 34. Dose profiles of the film (red) and planned (blue) in reference to the 
white crosshair in Figure 33a 
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(a)                                                                             (b) 
 
Figure 35. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) doses from the H&N plan delivery with no 
intentional offset 
 
             VERTICAL DOSE PROFILE                         HORIZONTAL DOSE PROFILE 
   
Figure 36. Dose profiles of the film (red) and reconstructed (blue) comparison in 




Figure 37. Illustration of the gamma distribution histogram taken over a selected 
region of interest 
 
Table 15. Summary of the gamma distribution from film versus reconstructed 
doses for the H&N plan 
 
Delivered Plan 
% of pixel with 





Normal - Day 1 97.9% 0.63 0.80 
Normal - Day 2 97.9% 0.62 0.80 
Normal - Day 3 99.0% 0.60 0.73 
Normal - Day 4 96.4% 0.68 0.90 
Normal - Day 5 98.3% 0.66 0.80 
All leaves -10 ms 97.1% 0.65 0.85 
All leaves +10 ms 98.5% 0.65 0.80 
Leaf #27 -10 ms 98.4% 0.67 0.81 






Table 16. Summary of the gamma distribution from film versus reconstructed 

































% of pixel with 
Gamma < 1 
Gamma 
index @ 10% 
Gamma 
index @ 5% 
Prostate - Day 1 (#1) 91.1% 0.97 1.10 
Prostate - Day 1 (#2) 90.9% 0.98 1.09 
Prostate - Day 2 (#1) 95.4% 0.86 0.99 
Prostate - Day 2 (#2) 97.5% 0.76 0.89 
Prostate - Day 3 (#1) 89.1% 1.01 1.14 
Prostate - Day 3 (#2) 92.0% 0.96 1.08 
Prostate - Day 4 (#1) 87.8% 1.04 1.17 
Prostate - Day 4 (#2) 89.8% 1.00 1.13 
All leaves +10 ms (#1) 95.7% 0.84 0.97 
All leaves +10 ms (#2) 95.4% 0.84 0.98 
All leaves -10 ms (#1) 93.2% 0.92 1.06 
All leaves -10 ms (#2) 96.9% 0.83 0.94 
All leaves +30 ms (#1) 96.1% 0.79 0.94 
All leaves +30 ms (#2) 94.5% 0.89 1.01 
All leaves -30 ms (#1) 90.1% 1.00 1.09 
All leaves -30 ms (#2) 89.5% 1.01 1.11 
Leaf 32-33 +10 ms (#1) 94.2% 0.88 1.03 
Leaf 32-33 +10 ms (#2) 92.4% 0.95 1.07 
Leaf 32-33 -10 ms (#1) 95.1% 0.87 0.99 
Leaf 32-33 -10 ms (#2) 96.7% 0.82 0.93 
Leaf 32-33 +30 ms (#1) 91.0% 0.97 1.12 
Leaf 32-33 +30 ms (#2) 90.8% 0.98 1.13 
Leaf 32-33 -30 ms (#2) 89.4% 1.01 1.14 
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Table 17. Summary of the gamma distribution from film versus reconstructed 































% of pixel with 





Lung - Day 1 (#1) 99.9% 0.50 0.58 
Lung - Day 1 (#2) 100.0% 0.47 0.54 
Lung - Day 2 (#1) 99.8% 0.55 0.64 
Lung - Day 2 (#2) 99.9% 0.63 0.71 
Lung - Day 3 (#1) 99.4% 0.53 0.62 
Lung - Day 4 (#1) 98.6% 0.66 0.78 
All leaves -10 ms (#1) 100.0% 0.44 0.50 
All leaves -10 ms (#2) 100.0% 0.37 0.42 
All leaves +10 ms (#1) 100.0% 0.46 0.52 
All leaves +10 ms (#2) 99.9% 0.44 0.50 
All leaves -30 ms (#1) 100.0% 0.38 0.45 
All leaves -30 ms (#2) 100.0% 0.34 0.41 
All leaves +30 ms (#1) 100.0% 0.49 0.56 
All leaves +30 ms (#2) 98.6% 0.75 0.84 
Leaf 32-33 -10 ms (#1) 99.9% 0.56 0.63 
Leaf 32-33 -10 ms (#2) 99.8% 0.58 0.65 
Leaf 32-33 +10 ms (#1) 99.4% 0.67 0.76 
Leaf 32-33 +10 ms (#2) 99.7% 0.60 0.69 
Leaf 32-33 -30 ms (#1) 99.8% 0.57 0.65 
Leaf 32-33 -30 ms (#2) 99.8% 0.56 0.64 
Leaf 32-33 +30 ms (#1) 97.0% 0.76 0.90 
Leaf 32-33 +30 ms (#2) 96.6% 0.77 0.90 
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CHAPTER 4.  CONCLUSIONS 
4.1 Conclusions 
The purpose of this study was to verify that the method used for DV can determine the 
actual dose delivered during treatment to within 2% for point dose measurements in the PTV and 
a gamma of less than 1.0 to at least 90% of a selected region for planar dose distribution 
measurements.  The investigated method accounted for variations in machine delivery due to 
beam output and/or leaf open time errors to determine the effective leaf open times for a given 
treatment delivery.  A DR is then computed using the energy fluence determined by the effective 
leaf open times. 
The following aims were used to determine the accuracy of the investigated method.  For 
Aim 1, three treatment plans were generated using a homogenous cylindrical phantom 
(TomoPhantom).  Contours from a H&N, prostate and lung patients were copied onto the 
phantom.  Planning parameters and optimization used standard clinical protocols.  The results for 
each plan resembled those of clinical patient plans. 
In Aim 2, plans were delivered and measured twice per day for several days to observe 
the statistical variations in the delivery.  In addition to the planned delivery, each plan were 
delivered with intentional offsets in the leaf open times and beam output.  Detector data were 
extracted after each delivery to be used to determine the effective leaf open times. 
Aim 3 consisted of using the effective leaf open times to generate the reconstructed dose 
of a delivery.  It was shown that the method of dose reconstruction based on DV was able to 
account for changes in the delivery due to intentional offsets in leaf open times and/or beam 
output.  Increasing the leaf open time to all leaves, for an entire delivery, lead to a reconstructed 
dose that has a higher dose to all structures relative to the planned dose.  Similarly, decreasing 
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the leaf open time of the center two leaves lead to a lower reconstructed dose along the central 
axis of the phantom relative to the planned dose. 
In Aim 4, comparisons were made between all measured dose and reconstructed dose.  
For point dose comparisons, differences between ion chamber measurements and reconstructed 
doses of all deliveries ranged from -2.1% to 0.9%.  With the exception of one measurement 
having a difference of greater than 2% from the reconstructed dose, a majority of the differences 
were approximately -1%.  For dose distribution comparisons, differences between film 
measurements and reconstructed doses for nearly all deliveries had a gamma index of less than 1 
for over 90% of the region of interest. 
The results from this study showed that the DV method employed by TomoTherapy 
DVPA software was able to reconstruct the delivered dose to within 2% of the measured point 
dose (using an ionization chamber) for the three plans with and without intentional delivery 
errors.  Dose distribution comparison between the film and DVPA reconstructed dose showed 
significant improvements in agreement when compared to that between the film and planned 
dose.  Gamma index distribution between the film and DVPA dose showed that over 85% of the 
dose distribution within the selected region for the three plans had a gamma value of less than 
1.0. 
4.2 Recommendation 
This study did not include MVCT images acquired prior to deliveries for dose 
reconstruction.  For actual patient treatments, daily variations in setup and anatomical position 
and/or shape exist.  Therefore, use of the daily MVCT image is needed along with DV to 
properly reconstruct dose that was delivered.  This requires that the IVDTs for both the kVCT 
and MVCT be accurate such that scans of the same object using either modality will result in the 
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same image (in terms of image value).  Monthly quality assurance should be put in place to keep 
both IVDTs up-to-date.  This would involve scanning a heterogeneous phantom, with known 
densities, on both a kVCT (used for diagnostic and treatment planning) and MVCT (treatment 
machine) scanner. 
4.3 Future Study 
 This study showed that DV and DR can be used to accurately determine the delivered 
dose to a typical clinical treatment delivery.  These tools provide the option to implement 
adaptive radiotherapy into a patient’s treatment plan during the course of treatment to correct for 
any deviations from the planned dose.  However, to properly utilize the full potential of adaptive 
radiotherapy, it is important to reconstruct the delivered dose based on the image of the patient 
during treatment (IGRT).  A deformable registration will need to be applied to this current image 
in order to get an accurate idea of the dose delivered to the targets and critical structures. 
By using the recommendation mentioned previously along with a system capable of 
deformable registration, DV and DR, one could perform clinical patient study to determine the 
importance of adaptive radiotherapy for helical tomotherapy.  This would require a DR for every 
delivery of a patient’s treatment.  After the final treatment, a cumulative dose can be computed 
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APPENDIX A:  H&N DOSE DISTRIBUTION COMPARISONS 
 
Additional dose distribution comparisons of the H&N plan for various deliveries. 
 
        
(a)                                                              (b) 
 
Figure A1. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
(dashed) dose from the H&N plan delivery with +10 msec center leaf offset 
 
 
VERTICAL DOSE PROFILE                        HORIZONTAL DOSE PROFILE 
   
Figure A2. Dose profile of the film (red) and planned (blue) in reference to the white 
crosshair in Figure A1a 
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(a)                                                                            (b) 
Figure A3. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the H&N plan delivery with +10 msec 
center leaf offset 
 
 
   VERTICAL DOSE PROFILE                        HORIZONTAL DOSE PROFILE 
   
Figure A4. Dose profile of the film (red) and reconstructed (blue) in reference to the 
white crosshair in Figure A3a 
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(a)                                                                            (b) 
Figure A5. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
(dashed) dose from the H&N plan delivery with +10 msec all leaves offset 
 
 
  VERTICAL DOSE PROFILE                        HORIZONTAL DOSE PROFILE 
   
Figure A6. Dose profile of the film (red) and planned (blue) in reference to the white 




        
(a)                                                                            (b) 
Figure A7. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the H&N plan delivery with +10 msec all 
leaves offset 
 
             VERTICAL DOSE PROFILE                         HORIZONTAL DOSE PROFILE 
   
Figure A8. Dose profile of the film (red) and reconstructed (blue) in reference to the 
white crosshair in Figure A7a 
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APPENDIX B:  PROSTATE DOSE DISTRIBUTION COMPARISONS 
 
Dose distribution comparisons for multiple deliveries of the prostate plan. 
   
(a)                                                                          (b) 
Figure B1. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 




             VERTICAL DOSE PROFILE                         HORIZONTAL DOSE PROFILE 
     
Figure B2. Dose profile of the film (red) and planned (blue) in reference to the white 




   
(a)                                                                          (b) 
Figure B3. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the prostate plan delivery with no 
intentional offset (5/1/08) 
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Figure B4. Dose profile of the film (red) and reconstructed (blue) in reference to the 











   
(a)                                                                          (b) 
Figure B5. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
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Figure B6. Dose profile of the film (red) and planned (blue) in reference to the white 












   
(a)                                                                         (b) 
Figure B7. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the prostate plan delivery with no 
intentional offset (5/8/08) 
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Figure B8. Dose profile of the film (red) and reconstructed (blue) in reference to the 













   
(a)                                                                          (b) 
Figure B9. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
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Figure B10. Dose profile of the film (red) and planned (blue) in reference to the white 










   
(a)                                                                         (b) 
Figure B11. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the prostate plan delivery with +30 msec 
center leaf offset (5/8/08) 
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Figure B12. Dose profile of the film (red) and reconstructed (blue) comparison in 











(a)                                                                         (b) 
Figure B13. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
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Figure B14. Dose profile of the film (red) and planned (blue) in reference to the white 











(a)                                                                         (b) 
Figure B15. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the prostate plan delivery with +30 msec 
all leaves offset (5/1/08) 
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Figure B16. Dose profile of the film (red) and reconstructed (blue) in reference to the 











(a)                                                                          (b) 
Figure B17. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
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Figure B18. Dose profile of the film (red) and planned (blue) in reference to the white 











(a)                                                                         (b) 
Figure B19. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the prostate plan delivery with -30 msec 
all leaves offset (5/1/08) 
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Figure B20. Dose profile of the film (red) and reconstructed (blue) in reference to the 










APPENDIX C:  LUNG DOSE DISTRIBUTION COMPARISONS 
 
    
(a)                                                                          (b) 
Figure C1. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
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Figure C2. Dose profile of the film (red) and planned (blue) in reference to the white 








    
(a)                                                                          (b) 
Figure C3. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
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Figure C4. Dose profile of the film (red) and reconstructed (blue) in reference to the 










    
(a)                                                                         (b) 
Figure C5. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
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Figure C6. Dose profile of the film (red) and planned (blue) in reference to the white 










    
(a)                                                                          (b) 
Figure C7. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the lung plan delivery with +30 msec 
center leaf offset (6/3/08) 
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Figure C8. Dose profile of the film (red) and reconstructed (blue) in reference to the 









    
(a)                                                                          (b) 
Figure C9. (a) Gamma display and (b) isodose distribution of a film (solid) vs. planned 
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Figure C10. Dose profile of the film (red) and planned (blue) in reference to the white 








    
(a)                                                                          (b) 
Figure C11. (a) Gamma display and (b) isodose distribution of a film (solid) vs. 
reconstructed (dashed) dose from the lung plan delivery with +30 msec 
center leaf offset (6/3/08) 
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Figure C12. Dose profile of the film (red) and reconstructed (blue) in reference to the 
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